GSK3B and cancer: Interestingly, 9-ING-41, a novel GSK3B inhibitor developed by Actuate Therapeutics, is currently undergoing phase 1 and phase 2 trials as a single agent and in combination with cytotoxic agents, in patients with refractory cancers, including CRCs.